Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A set of biogenetically interesting polyhalogenated acetogenins from Ptilonia magellanica

  • Gallardo, Amalia
  • Cueto, Mercedes
  • Díaz-Marrero, Ana Raquel
  • Rosa, José M. de la
  • Fajardo, Víctor
  • San-Martín, Aurelio
  • Darias, José
Ptilonines A−F, pyranosylmagellanicus D−E and magellenediol are previously undescribed acetogenins isolated from the red alga Ptilonia magellanica. Their structures were determined from spectroscopic evidence. The absolute configuration of the known pyranosylmagellanicus A, was established by derivatization with (R)− and (S)−α−methoxy −α−phenylacetic acids (MPA). Ptilonines exhibit an unusual halogenation pattern, that may confer evolutionary advantages to Ptilonia magellanica, for which a biogenetic origin is proposed. The antimicrobial effect of some of these compounds was evaluated., This work was supported by the Ministerio de Ciencia e Innovación (SAF2009-0839 and RTA 2015-00010-C03-02). ARDM acknowledges funding from IMBRAIN project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN). A.B.G. would like to thank Convenio Universidad de Magallanes (Chile) and CSIC, project 2009CL0031 and Programa PR-F2-03-CRN16 for financial support., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake

  • Castro-Hernández, Javier
  • Afonso-Oramas, Domingo
  • Cruz-Muros, Ignacio
  • Salas-Hernández, Josmar
  • Barroso-Chinea, Pedro
  • Moratalla, Rosario
  • Millan, Mark J.
  • González-Hernández, Tomás
The dopamine (DA) transporter (DAT), a membrane glycoprotein expressed in dopaminergic neurons, clears DA from extracellular space and is regulated by diverse presynaptic proteins like protein kinases, α-synuclein, D2 and D3 autoreceptors. DAT dysfunction is implicated in Parkinson's disease and depression, which are therapeutically treated by dopaminergic D2/D3 receptor (D2/D3R) agonists. It is, then, important to improve our understanding of interactions between D3R and DAT. We show that prolonged administration of pramipexole (0.1 mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution. The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R−/−), yet unaffected in mice genetically deprived of D2R (D2R−/−). Pramipexole treatment induced a physical interaction between D3R and DAT, as assessed by co-immunoprecipitation and in situ proximity ligation assay. Furthermore, it promoted the formation of DAT dimers and DAT association with both D2R and α-synuclein, effects that were abolished in D3R−/− mice, yet unaffected in D2R−/− mice, indicating dependence upon D3R. Collectively, these data suggest that prolonged treatment with dopaminergic D3 agonists provokes a reduction in DA reuptake by dopaminergic neurons related to a hitherto-unsuspected modification of the DAT interactome. These observations provide novel insights into the long-term antiparkinson, antidepressant and additional clinical actions of pramipexole and other D3R agonists., This study was supported by the grants BFU2010-21130 and BFU2013-47242-R (Ministerio de Ciencia e Innovación) to T G-H, BFU2010-20664 (Ministerio de Ciencia e Innovación), PNSD, to R M, and the IMBRAIN project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN), funded under the 7th Framework Programme (Capacities). J C-H was supported by a predoctoral fellowship from the Fundación Canaria de Investigación y Salud (ID54), J S-H was partially supported by the Agencia Canaria de Investigación, Innovación y Sociedad de la Información (SE-10/19), and P B-C was supported by a grant from the Campus de Excelencia Internacional (FEDER, ULL, CEI 10/00018-EDU/903/2010).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Protein homeostasis defects of alanine-glyoxylate aminotransferase: New therapeutic strategies in primary hyperoxaluria type i

  • Pey, Ángel L.
  • Albert, Armando
  • Salido, Eduardo
16 pags, 5 figs, Alanine-glyoxylate aminotransferase catalyzes the transamination between L-alanine and glyoxylate to produce pyruvate and glycine using pyridoxal 5′-phosphate (PLP) as cofactor. Human alanine-glyoxylate aminotransferase is a peroxisomal enzyme expressed in the hepatocytes, the main site of glyoxylate detoxification. Its deficit causes primary hyperoxaluria type I, a rare but severe inborn error of metabolism. Single amino acid changes are the main type of mutation causing this disease, and considerable effort has been dedicated to the understanding of the molecular consequences of such missense mutations. In this review, we summarize the role of protein homeostasis in the basic mechanisms of primary hyperoxaluria. Intrinsic physicochemical properties of polypeptide chains such as thermodynamic stability, folding, unfolding, and misfolding rates as well as the interaction of different folding states with protein homeostasis networks are essential to understand this disease. The view presented has important implications for the development of new therapeutic strategies based on targeting specific elements of alanine-glyoxylate aminotransferase homeostasis. © 2013 Angel L. Pey et al., This work was supported by the Spanish ministry of Science and Innovation (RYC2009-04147 and CSD2009-00088 to Angel L. Pey, SAF2011-23933 to Eduardo Salido, and CSD2006-00015 and BFU2011-25384 to Armando Albert), Junta de Andalucia (P11CTS-7187 A.L.P.), and European Union (FP7-REGPOT-CT2012-31637-IMBRAIN to E.S.).
Repositorio Institucional de la Universidad de Burgos (RIUBU)
Publication Artículo científico (JournalArticle)

Chloro-Furanocembranolides from Leptogorgia sp. Improve Pancreatic Beta-Cell Proliferation

  • Villa Pérez, Pablo .
  • Gallardo, Amalia B. .
  • Díaz Marrero, Ana R. .
  • Rosa, José M. de la .
  • Croz, Luis D’ .
  • Perdomo Hernández, Germán M.
  • Cózar Castellano, Irene
  • Darias, José .
  • Cueto, Mercedes .
Type 2 diabetes (T2DM) is a complex disease linked to pancreatic beta-cell failure and insulin resistance. Current antidiabetic treatment regimens for T2DM include insulin sensitizers and insulin secretagogues. We have previously demonstrated that leptolide, a member of the furanocembranolides family, promotes pancreatic beta-cell proliferation in mice. Considering the beneficial effects of leptolide in diabetic mice, in this study, we aimed to address the capability of leptolide to improve insulin resistance associated with the pathology of obesity. To this end, we tested the hypothesis that leptolide should protect against fatty acid-induced insulin resistance in hepatocytes. In a time-dependent manner, leptolide (0.1 µM) augmented insulin-stimulated phosphorylation of protein kinase B (PKB) by two-fold above vehicle-treated HepG2 cells. In addition, leptolide (0.1 µM) counteracted palmitate-induced insulin resistance by augmenting by four-fold insulin-stimulated phosphorylation of PKB in HepG2 cells. In vivo, acute intraperitoneal administration of leptolide (0.1 mg/kg and 1 mg/kg) improved glucose tolerance and insulin sensitivity in lean mice. Likewise, prolonged leptolide treatment (0.1 mg/kg) in diet-induced obese mice improved insulin sensitivity. These effects were paralleled with an ~50% increased of insulin-stimulated phosphorylation of PKB in liver and skeletal muscle and reduced circulating pro-inflammatory cytokines in obese mice. We concluded that leptolide significantly improves insulin sensitivity in vitro and in obese mice, suggesting that leptolide may be another potential treatment for T2DM, Ministerio de Ciencia e Innovación (SAF2009-0839 and RTA 2015-00010-C03-02). ARDM acknowledges funding from IMBRAIN project (FP7-REGPOT-2012-CT2012-31637-IMBRAIN) and from Cabildo de Tenerife (Agustín de Betancourt Programme). A.B.G. would like to thank Convenio Universidad de Magallanes (Chile) and CSIC, project 2009CL0031, for financial support.